All In Biotech

Free tool

FAERS Monitor: Gastrografin

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 011245 or its brand name (Gastrografin, Diatrizoate Meglumine, Diatrizoate Sodium). Reports on generic versions are filed under their own applications.

Reports

372

Serious

260

70% of reports

Hospitalization

149

Death reported

54

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • urticaria31
  • diarrhoea27
  • nausea24
  • vomiting23
  • no adverse event22
  • pruritus19
  • drug ineffective17
  • off label use17
  • dyspnoea16
  • rash13
  • sepsis12
  • hypotension11
  • abdominal pain10
  • anaemia10
  • aspiration10

Reports by year received

View as table
YearReports
20059
200612
20077
200827
200915
201027
201122
201220
201317
201416
201520
201630
201722
201822
201919
202013
202125
202217
202314
20247
20258
20263

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,787 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
aspirationSignal1051.728.0447
urticariaSignal3110.57.5258
no adverse eventSignal226.94.6105
sepsisSignal126.13.546
hypotensionSignal113.11.714
anaemiaSignal103.01.611
pruritusSignal192.81.821
vomitingSignal232.81.925
abdominal painSignal102.41.37
diarrhoeaSignal272.41.621
nausea241.71.27
rash131.71.03
dyspnoea161.61.03
off label use171.10.70
drug ineffective170.70.52

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.